Brimonidine ophthalmic solution 0.1% — Competitive Intelligence Brief

Brimonidine ophthalmic solution 0.1% (Brimonidine ophthalmic solution 0.1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Ophthalmology.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Ophthalmology Small molecule

Target snapshot

Brimonidine ophthalmic solution 0.1% (Brimonidine ophthalmic solution 0.1%) — Allergan. Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brimonidine ophthalmic solution 0.1% TARGET	Brimonidine ophthalmic solution 0.1%	Allergan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Ropivacaine + Dexmedetomidine	Ropivacaine + Dexmedetomidine	Sahiwal medical college sahiwal	marketed	Local anesthetic + alpha-2 adrenergic agonist combination	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)
oxymetazoline-fluticasone propionate	oxymetazoline-fluticasone propionate	Brian J Lipworth	marketed	Nasal decongestant/corticosteroid combination	Alpha-2 adrenergic receptor; glucocorticoid receptor
Catapresan TTS 2	Catapresan TTS 2	Heart Care Foundation	marketed	Central alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Brimonidine/Timolol mixed combination	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Dexmedetomidine 0.5 microgram/kg	Dexmedetomidine 0.5 microgram/kg	Sindh Institute of Urology and Transplantation	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

1. Allergan · 3 drugs in this class
2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
3. National Cancer Institute, Egypt · 2 drugs in this class
4. The University of Hong Kong · 2 drugs in this class
5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
6. Fayoum University Hospital · 1 drug in this class
7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
10. KAT General Hospital · 1 drug in this class